Tau PET Imaging Using 18F-AV-1451
Recruiting
This study will evaluate a new radioactive compound, 18F-AV-1451, in identifying tau tangles in positron emission tomography (PET) scans. Tau is a protein that accumulates abnormally in the brains of people with Alzheimer's disease and other neurodegenerative disorders.
| Minimum Age | Maximum Age | Gender | Healthy Volunteers |
|---|---|---|---|
| 65 Years | N/A | All | No |
- Able to undergo a lumbar puncture or has previously had one
- Able to undergo PET and magnetic resonance imaging scans of the brain
- Negative urine pregnancy test 24 hours before drug administration
- Any condition that could increase participant's risk, limit ability to undergo the procedures, or interfere with data collection and analysis
- History of Torsade de Pointes, a rare heart arrhythmia, or use of medications that prolong the QT interval
- Known hypersensitivity to the compound T807 or its other ingredients
- Severe claustrophobia
- Pregnant or breastfeeding
In this Phase II study, participants will receive an intravenous injection of the compound 18F-AV-1451 and undergo a PET scan to show measurement of tau deposition. Participants also may undergo optional PET imaging with another compound to measure glucose use in the brain and may volunteer for follow-up T807-PET imaging at least 2 years after the initial scan. Researchers will evaluate changes in T807-PET measures over time, as well as the association between levels of tau and changes in cerebrospinal fluid biomarkers and cognitive function.
| Name | City | State | Zip | Status | Primary Contact |
|---|---|---|---|---|---|
|
Washington University School of Medicine |
Saint Louis | Missouri | 63110 | Recruiting |
Kelley Jackson 314-362-1558 jacksonk@wustl.edu |
Washington University School of Medicine
| Name | Role | Affiliation |
|---|---|---|
| Tammie Benzinger, PhD | Principal Investigator | Washington University School of Medicine |
| Name | Phone | |
|---|---|---|
| Theresa Butler | 314-362-1558 | butlert@wustl.edu |
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD in Humans